Dorothy Bailey

President chez Exo Therapeutics, Inc.

Health Technology

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Thomas Cahill	M	37	Exo Therapeutics, Inc. Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.	-
Nagesh Mahanthappa	M	59	Exo Therapeutics, Inc. Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.	3 ans
Kanishka Pothula	M	39	Exo Therapeutics, Inc. Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.	3 ans
Thilo Schroeder	M	42	Exo Therapeutics, Inc. Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.	3 ans
Michael Bruce	M	-	Exo Therapeutics, Inc. Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.	4 ans